Information on neonatal-tetanusrelated mortality rates was obtained in 2 independent assessments of causes of childhood death. The first consisted of a special study of causes of neonatal and postneonatal mortality in the Matlab study area in 1982/83; this study undertook retrospective semistructured interviews with the mother or closest kin of the deceased child to ascertain the sequence of symptoms experienced prior to death and to assign a specific cause of death, including neonatal tetanus.'5 These histories were reviewed, and a probable cause of death was assigned by a public health physician. The second data source, from 1986 onward, was a more rigorous system of cause-of-death assignment implemented throughout the entire Matlab study area, in recognition of the limitations of the previous system with respect to causes of death such as neonatal tetanus. A special questionnaire was administered by trained female interviewers to the families of all infants who died between the 4th and 21st days of life. The main criteria for neonatal tetanus death included no apparent complications at birth, good suckling and crying patterns during the initial 48 hours of life, difficulty in suckling and lockjaw as initial symptoms, spasms of the neck and body, rigidity, and signs of umbilical stump infection.16 All death records were reviewed, and a cause of death was assigned by independent reviewers (initially a team of physicians and subsequently a specially trained medical assistant). In both assessments, cause of death was assigned according to the World Health Organization's International Classification ofDiseases. '7"18 Results Table 1 presents data on the characteristics of the 3 vaccine groups. It is evident that the 3 groups were highly similar in terms of age and socioeconomic indicators such as household area and level of maternal education. Similar conclusions were reached in comparing the characteristics of specific birth cohorts; maternal age and parity were similar for the 3 vaccine groups for births occurring during 1985/86 as well as for other birth cohorts (data not shown). On the whole, these results provide strong support for the integrity of the randomized design of the 1974 vaccine trial. Maternal Tetanus Immunization than control group infants whose mothers received cholera toxoid through 1983/84, a period of 10 years postvaccination. While neonatal mortality rates among the 1-injection group were also consistently lower than those for the control group, these differences largely failed to attain statistical significance.
Differences across vaccine groups are even more pronounced when 4-to 14-day mortality-the primary risk period for neonatal tetanus-is considered (Table 3) . Among infants of mothers who received 2 injections of tetanus-diphtheria toxoid, 4-to 14-day mortality levels during the subsequent 10-year period were significantly lower, at levels roughly one half those for the control group. Among the 1-injection group, 4-to 14-day mortality rates were significantly lower than those for the control group during the 4 years immediately following the vaccine trial (1975 through 1978) . Although subsequent mortality rates were also lower than those for the control group, these differences failed to attain statistical significance.
Previous research has shown that more than half of all 4-to 14-day deaths in the Matlab area are attributable to causes other than neonatal tetanus. '9 We therefore also considered neonatal-tetanus-related mortality rates for those years in which reliable data on cause of death were available from special studies (1982/83 and 1986/87) ( Table 4) . Two injections of tetanus toxoid provided significant protection against death from neonatal tetanus in both the 1982/83 and 1986/87 birth cohorts (3.8 vs 14.4 deaths per 1000 live births and 2.0 vs 10.0 deaths per 1000 live births), and the differences were highly significant. Neonataltetanus-related mortality rates were also discernibly lower among the 1-injection group in both the 1982/83 and 1986/87 birth cohorts and comparable to rates for the 2-injection group (5.6 vs 14.4 deaths per 1000 live births and 3.3 vs 10.0 deaths per 1000 live births), although both differences failed to attain statistical significance.
Discussion
The 1974 cholera vaccine trial undertaken in the Matlab study area provided a unique opportunity to assess the duration and magnitude of mortality effects resulting from maternal tetanus immunization. Because tetanus toxoid was provided as the placebo as part of a double-blind trial randomized on an individual basis, the results are free from the problems of selection bias commonly associated with evaluations of health interventions such as immunization. Several potential limitations of the present study should nevertheless be noted. First, the possibility of error in the assignment of cause of neonatal tetanus death cannot be ruled out. While there has been a concerted effort to strengthen cause of childhood death assignment in the Matlab area over the last decade, cause of death data based on lay reporting invariably remain subject to a certain degree of classification error. 20 In the present study, however, since cause-of-death assignments were made independently of knowledge of the mother's 1974 tetanus vaccination status, any classification error that did occur should have been randomly distributed across all 3 vaccination groups. Misclassification of cause of death would therefore not account for any of the observed differences in mortality among vaccination groups.
Second, it is possible that the results reported were influenced by the confounding effects of tetanus vaccination from sources other than the 1974 cholera vaccine trial. One possible source was cholera vaccine trials held by the International Centre for Diarrhoeal Disease Research during the 1960s, in which tetanus toxoid was also used as a placebo.322 An earlier study conducted in Matlab, however, found that the proportion of women in the 1974 cholera vaccine trial who received tetanus toxoid through participation in the earlier vaccine trials was very small (only 6%).3 Acceptance of tetanus vaccination from other sources following the 1974 vaccine trialmost notably, through the national immunization program-represents a second and potentially more serious source of bias. By limiting the prospective period of our study to 1987, when tetanus coverage levels nationally and in the Matlab comparison area still remained very low, we sought to minimize the extent of bias introduced by tetanus vaccination from sources other than the 1974 trial. Moreover, given the doubleblind design of the 1974 cholera vaccine trial, any subsequent acceptance of tetanus vaccination could be expected to take place largely independently of 1974 vaccination status and, therefore, to be randomly distributed across all 3 vaccination groups. To the extent that subsequent acceptance of maternal tetanus vaccination did occur, unvaccinated mothers would also be expected to have disproportionately benefited, as children of mothers who received tetanus toxoid during the 1974 trial would continue to experience significant levels of residual protection against the risk of The results of our study provide strong evidence that maternal tetanus toxoid vaccination confers significant protection against the risk of neonatal tetanus for a much longer duration than previously documented. Our analysis has shown that children whose mothers received 2 injections of tetanus toxoid in the 1974 vaccine trial experienced consistently lower 4-to 14-day mortality risks than children of unimmunized mothers during the 10- ule of maternal tetanus toxoid. From the standpoint of immunization strategy in settings such as South Asia, where immunization coverage levels remain low and health infrastructures are weak, our findings argue strongly for according highest priority to the goal of universal coverage of all reproductive-aged women with a minimum of 2 tetanus toxoid injections. Our results also suggest that initiating programs to reach young women with 2 doses of tetanus toxoid prior to the onset of childbearing (and even during adolescence) would confer a high degree of protection against the risk of neonatal tetanus throughout most, if not all, of the primary reproductive years. D
